Background. Parathyroid tumors are mostly considered monoclonal neoplasms, the rationale for focused parathyroidectomy in primary hyperparathyroidism. We reported that flow sorting parathyroid tumor cells and methylation-sensitive polymerase chain reaction (me-PCR) of polymorphic human androgen receptor gene and phosphoglycerate kinase gene alleles in deoxyribonucleic acid reveals that ≤35% of parathyroid tumors are polyclonal. We sought to confirm these findings and assess for clinical relevance. Methods. Parathyroid tumors from 286 female primary hyperparathyroidism patients were analyzed for clonal status. Tumor clonal status was compared with clinical variables and operative findings. Statistical analysis was performed and significance was established at P < .05. Results. In the study, 176 (62%) patients were informative for human androgen receptor gene and/or phosphoglycerate kinase gene. Assignment of clonal status was made in 119 (68%) tumors, of which 64 (54%) were monoclonal and 55 (46%) were polyclonal. Comparison of tumor clonal status to clinical variables in patients with complete operative data (N = 82) showed that while clinical features were the same between tumor types, patients with polyclonal tumors more often had multiple gland disease (risk ratio 4.066, confidence interval, 1.016-16.26; P = .039) potentially missed at unilateral neck exploration. Conclusion. This work confirms that primary hyperparathyroidism is often the result of polyclonal tumors and that parathyroid tumor clonal status may be associated with multiple gland disease.
Parathyroid adenoma originating from a single parathyroid gland is the most common cause of nonfamilial primary hyperparathyroidism (PHPT). 1 Less commonly, PHPT patients have primary chief cell hyperplasia or multiple adenomas as the cause of their disease. These processes of parathyroid neoplasia cannot be predicted on clinical grounds and can be difficult to distinguish on pathologic examination. Their importance lies in their relationship with multiple gland disease and its impact on approach to parathyroidectomy (PTX) and results of surgery. Removal of single adenoma by either a focused (i.e., unilateral) or bilateral exploration and PTX is likely curative; however, cure of PHPT due to multiple gland hyperplasia can be less reliable after surgery. 2 The somatic mutation theory of cancer holds that a finite set of somatic mutations in deoxyribonucleic acid (DNA) result in the transformation of cells and their progression to malignancy. 3 According to this framework, parathyroid adenomas in nonfamilial PHPT are predicted to be monoclonal expansions of a single transformed parathyroid cell, whereas hyperplasias may be the result of poly-or oligoclonal expansions of multiple cells due to exogenous stimuli. Tumor clonal status then may be viewed as a potential surrogate for both underlying etiology and type of parathyroid neoplasia. The topic of parathyroid tumor clonal status has been the subject of several studies with mixed and controversial results. [4] [5] [6] [7] In particular, the finding of parathyroid tumor polyclonal status by several investigators has been questioned due to methodologic approach (e.g., use of microdissection to remove polyclonal stroma) and the assays used to assign tumor clonal status.
We previously conducted a study of parathyroid tumors from patients with nonfamilial PHPT due to single gland disease in which cells isolated from these tumors were dispersed and flow sorted to yield purified populations of oxyphil and chief cells. These isolated cells were analyzed both functionally and genetically, and our results showed that a significant proportion (9/14, 36%) of apparent adenomas were in fact polyclonal. 8 We have examined an expanded cohort of 119 patients and have found that a significant proportion (≤46%) of patients have polyclonal parathyroid tumors as the cause of their disease and that these patients are otherwise indistinguishable based on clinical and biochemical criteria. In addition, among 82 patients well-characterized in terms of demographic, biochemical, operative, and pathologic data we found that polyclonal tumor status is associated with the presence of multiple gland disease that may be missed with unilateral exploration. Our findings indicate that the etiology of PHPT is heterogeneous and that underlying parathyroid tumor clonal status may be important to disease outcome after PTX.
Methods
Primary parathyroid tumors and clinical data were obtained from consenting PHPT patients under institutional review board-approved protocols at The University of Maryland Baltimore (UMB; N = 135, 2012-2016) and Duke University (N = 151, 2001-2012). De-identified tumor samples were transferred from Duke to UMB under a materials transfer agreement between the 2 institutions. Tumor samples were collected from resected tumors in the operating room and immediately placed in liquid nitrogen. Duplicate samples were fixed in buffered formalin, embedded, sectioned, stained with hematoxylin and eosin, and examined to ensure parathyroid tumor identity and cellularity. Parathyroid tumor samples were kept at −80°C until use. Peripheral blood lymphocytes (PBLs) were isolated from patientmatched whole blood using RBC Lysis Buffer (Biolegend, CA).
Genomic DNA extraction from peripheral blood lymphocytes and parathyroid adenoma tissue was performed using DNeasy Blood & Tissue Kit (Qiagen, Hilden, Germany). Clonal status at the human androgen receptor gene (HUMARA) locus was determined via restriction enzyme (HhaI) digestion and PCR amplification following the procedure described by Allen et al. 9 HUMARA primer sequences were: primer 1, 5'-TCCAGAATCTGTTCCAGAGCGTGC -3'; and primer 2, 5'-GCTGTGAAGGTTGCTGTTCCTCAT-3'. The PGK clonality assay was modified based on the method described by Gilliland et al. 10 The PGK primer sequences were: primer 1, 5'-TGTGGGGCGGTAGTGTGGGCCCTGTTCCTG-3'; and primer 2, 5'-AACCGTGTTGGCAAGTGACTAGAGATCCAC-3'. A schematic diagram depicting the me-PCR assays for HUMARA and PGK is shown in Fig 1. De-identified clinical and research data were maintained in separate password-protected databases linked by a study code. Clonal status from de-identified tumor samples and clinicopatholofic data were analyzed for significant association using SPSS software (International Business Machines, Armonk, NY).
Results
PBL samples from 286 PHPT patients were analyzed for clonal status by me-PCR at both the HUMARA and PGK loci. Of these patients, 176 (62%) were informative for either or both assays in PBL (Fig 2, solid black arrowhead) . Definitive assignment of parathyroid tumor clonal status in these informative patients was made in 119 patients based on clear identification of appropriate size PCR bands in undigested and HhaI digested DNA from parathyroid tumor samples (Fig 2, solid grey arrowhead ). There were 57 patient tumor samples that yielded ambiguous clonal results on repeated testing and were deemed an assay failure. Reasons behind the unclear results included insufficient tumor tissue for repeat assay, failure of PCR reactions in tumor DNA, inability to resolve appropriate sized bands on the gel, or failure of control (undigested) tumor DNA to show bands as expected from the results of the corresponding patient's PBL sample. Of the 119 patients with clearly assigned clonal status, 82 patients had complete clinical and operative records available for review (Fig 2, hatched arrowhead) .
Representative me-PCR gels from 2 monoclonal and 1 polyclonal tumors are shown in Fig 3. Amplification of alleles in control DNA from PBL and undigested tumor DNA with primers specific for HUMARA (Fig 3, lanes 1-3) yielded 2 bands of ≈280 bp, differing in size by the presence of (CAG)N repeats. Amplification of monoclonal tumor DNA digested with HhaI (Fig 3, lane 4 ) resulted in loss of one unmethylated HUMARA allele from the single clone yielding a single band (solid arrows), whereas digestion of polyclonal tumor DNA with HhaI resulted in loss of one or the other unmethylated alleles from multiple clones resulting in 2 bands (hatched arrows). Similarly, amplification of alleles in control DNA from PBL and undigested tumor DNA with primers specific for PGK followed by BstXI digestion of PCR products yielded 2 bands of 1021 and 597 bp (Fig 3, lanes 5-7) . Amplification of monoclonal tumor DNA digested with HhaI (Fig 3, lane 8 ) resulted in loss of either unmethylated PGK allele with or without the BstXI restriction site from a single tumor clone resulting in a single band of either 1021 bp or 597 bp (solid arrows). In contrast, polyclonal tumor DNA digested with HhaI resulted in loss of one or the other unmethylated alleles with and without the BstXI restriction site from multiple clones resulting in both bands (hatched arrows).
Comparison of clinical and laboratory data of 119 patients with unambiguously determined tumor clonal status indicates that these patients are indistinguishable in terms of age, race, body mass index, biochemical and imaging results at presentation (Table I) . Symptom data was not available for the Duke patients; however, among 62 UMB patients with preoperatively recorded symptoms, there was no difference in the presence or type of symptoms reported between patients with monoclonal and polyclonal tumors. Patients with monoclonal tumors showed a statistically nonsignificant but nonetheless notable tendency toward reduced bone density (76% vs 54% with osteoporosis/osteopenia) and positive sestamibi scans (66% vs 50% positive). The frequency of polyclonal tumors was the same in the patients from UMB (29/63, 46%) and Duke (26/56, 46%).
Analysis of data from the subset of 82 patients with unambiguous tumor clonal status and complete operative and pathologic information revealed that these patients were not different in terms of operative approach taken, intraoperative PTH kinetics, postoperative calcium, and the frequency of persistent disease (Table II) . There was a notable, but statistically nonsignificant trend toward higher average postoperative PTH levels in patients with polyclonal Table III . We observed that patients with polyclonal tumors who had unilateral neck exploration were less likely to have multiple abnormal glands identified and removed than those patients who had bilateral exploration (1/16 vs 8/14, P = .025) suggesting that patients with polyclonal tumors may have abnormal glands missed at unilateral neck exploration. No such difference was observed in patients with monoclonal glands who had unilateral exploration or in patients with either tumor type who had bilateral exploration.
Discussion
In this study, we report the largest analysis of parathyroid tumor clonal status to date, showing that a significant proportion of patient with PHPT have polyclonal rather than monoclonal tumors. These findings support results of smaller series that question the notion that most parathyroid tumors are monoclonal in origin (Table IV) . [4] [5] [6] [7] [8] 11 Our results also show that patients with polyclonal tumors are at greater risk for having multiple gland disease, and these glands may go undiscovered at unilateral neck exploration. Importantly, patients with polyclonal tumors are presently not discernable by standard clinical criteria justifying future investigation for the cause and markers of polyclonal parathyroid neoplasia.
The method of assigning tumor clonal status in this study is worthy of close scrutiny. Me-PCR has been used in numerous studies of tumor clonality, including parathyroid and is considered a reliable method of determining clonal status in endocrine neoplasia. 6, 12 While this assay method could be subject to inaccuracy due to somatic tumor DNA methylation, this seems unlikely. Most recently, Corrado et al reported a HUMARA me-PCR analysis of clonal status in 2 tumors from patients with neonatal severe hyperparathyroidism, finding that both tumors were polyclonal expansions. 13 They used a second, independent method, array comparative genomic hybridization, to examine gain/loss of chromosomal material and found concordance between the 2 methods in terms of parathyroid tumor clonal status. Future studies likely will need to use sequence based approaches as secondary methods to confirm me-PCR assignment of tumor clonal status.
14 Strengths of our study include the large number of tumors available for analysis, the use of multiple assays to assign tumor clonal status, and the careful procurement and processing of samples to ensure that contaminating stroma did not yield spurious assignment of polyclonal tumor status. The most significant limitation of the study is that the me-PCR HUMARA and PGK clonality assays are based on the biology of X-inactivation and therefore can be applied only to female patients. To minimize potential assignment error, we included only the 119 patients with informative alleles in PBL who had unambiguous clonality assay results in undigested and digested tumor DNA to determine of the frequency of clonal status in the patients of the study. While it is possible that this filter could introduce bias to the study and overestimate the frequency of polyclonal disease, this seems unlikely because there is no biologic reason why technical failure or ambiguity of results based on size difference of the maternal and paternal HUMARA and PGK alleles would occur differentially in patients with single or multiple gland disease, and so is unlikely to change the conclusion. Future studies using sequence-based fragment analysis of HUMARA alleles may improve upon ambiguous assignment by the gel-based method. 13 The retrospective nature of the analysis and availability of complete surgical and outcome data for 82 of the 119 tumors examined likely makes the study underpowered to detect small, but clinically meaningful clinical differences between tumor types. Finally, the absence of long-term biochemical and symptom followup for these patients (median follow-up 10 months) does not permit us to determine whether tumor clonal status matters to disease recurrence over time. A prospective, multicenter validation study is in development to address this important question.
Despite the limitations of this study, it is reasonable to conclude from our data that all parathyroid tumors are not genetically the same (i.e., monoclonal) and that parathyroid tumors may result from differing underlying etiologies, including a secondary stimulus leading to hyperplasia, polyclonal expansion and apparent adenoma formation. Whether primary chief cell hyperplasia described histologically and associated with multiple gland disease and poorer surgical outcomes is in fact polyclonal and reactive to an exogenous stimulus (e.g., chronic vitamin D deficiency) is an interesting question that will require future study. 2, 15 Regardless, if future work in expanded populations of PHPT confirm that parathyroid tumors clonal status is important to outcome, then it will be critically important to determine clonal status before surgery. Development of an actionable blood biomarker test to predict accurately either a monoclonal tumor amenable to directed PTX, or a polyclonal tumor better approached by bilateral neck exploration, or treatment of the driving stimulus (e.g., vitamin D deficiency) could become of great importance.
This work represents the first assessment of the frequency and clinical significance of parathyroid tumor clonal status in PHPT. These results confirm our published findings that PHPT is often the result of polyclonal parathyroid tumors, a conclusion that refutes the idea that all parathyroid tumors are monoclonal. While biochemical and demographic features of patients with both types of parathyroid tumors are similar, patients with polyclonal tumors more often have multiple gland disease that may be missed at unilateral exploration. Our results support the notion that PHPT is a heterogeneous disorder and reinforces the importance of developing a better understanding of underlying parathyroid tumor biology as a basis of improving treatment of PHPT.
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Dr Sareh Parangi (Boston, MA): Thanks. This is really fantastic work and very clinically relevant. I do not know if I missed it, but is there any imaging, preoperative imaging tool that could have predicted the polyclonal people?
Dr John A. Olson, Jr.: Good question. Buried in the first table I showed you were the results of the MIBI scanning performed in the 2 groups of patients. And although it did not reach statistical significance, we found that at least in the preliminary data, that the MIBI scanning was negative much more often in the polyclonal patients, which is what you might expect, as has been pointed out for multiple gland disease. To really hammer that, though, and have a definitive conclusion would require more patients, and this is a prospective study.
Dr Rebecca S. Sippel (Madison, WI): I think this is fascinating work. I think you are really getting at the heart of the issue, which is, we do not really understand what causes primary hyperparathyroidism and understand the disease. In order to know how to treat it, you have to understand what causes it.
I think, as you have alluded to, obviously they have a high risk of recurrence if it is polyclonal. It would be really helpful for us to know even postoperatively if this polyclonal disease, then we could change the follow up in what we educate the patients. Is there a simple way our pathologist could do testing on specimens to say that this is a polyclonal specimen so that we could then alter our postoperative management? Dr John A. Olson, Jr.: At the moment, there is not. As a followup study that we are in the midst of, we have engaged with an endocrine pathologist who we are sending blinded specimens to see if there are histologic differences.
As you know, you often just get parathyroid tissue or adenoma or hyperplasia. We are going to try to dig deeper and find out if there are histologic features. That is going to be the most likely application of the humoral assay. And PGK assays, first of all, are only applicable to female patients due to the X linked inactivation biology, and so I do not think that assay will be routine, and it is a little bit finicky, as you can see from our flow diagram.
I think, you know, if this is true that it matters, and if it is important to know either preoperatively or postoperatively, you might envision, if you can determine mutational status that could be measured in exosome, you know, of the blood, you might be able to make a guess as to whether they are monoclonal or polyclonal. But it is a few steps down the line.
Dr Dr Mira Milas (Phoenix, AZ): Thank you, John, for a wonderful presentation and even more for continuing to study this topic so all of us can have an understanding of the biology.
Probably nationwide, there are many tissue banks of parathyroid tissue, both from cryopreserved sources that are unused and routine tissue banking. How is it possible to send samples for this kind of testing, and would you expect any variation from parathyroid tissues stored at different centers?
Dr John A. Olson, Jr.: Good question, Mira. So, the last question is easiest. It is a DNA based test, so a banked tumor should have stable DNA and be suitable for the analysis and the methylation is retained.
As far as retrospective studies, those are certainly feasible. What I have learned in our experience is there is no substitute for a prospective study where you can carefully ask, you know, symptom questions, bone density recovery questions, careful bioidentical follow up that, you know, as good as we all try to make our retrospective databases, there is missing data sometimes and things. And so I far prefer to enlist you in a prospective study to send, you know, samples, and then we would have case report forms and things like that.
So, I am hoping this is ready more for a prospective type of study where we can carefully tease out some of the parts of the last question, you know, does bone density recover equally among polyclonal versus monoclonal, et cetera, et cetera.
Dr Mira Milas (Phoenix, Arizona): That is wonderful. I am willing to be enlisted.
Dr Collin J. Weber (Atlanta, GA): John, I enjoyed your paper very much. One comment, which is, would you agree that the multigland polyclonal lesions should probably be labeled as hyperplasias in the historical context where an adenoma has a removed normal, et cetera, et cetera, et cetera?
And can you illuminate for me how your data differs from Arnold's, who came down pretty heavily on the side that adenomas are monoclonal and there is another group of patients that are hyperplasias that are polyclonal?
Dr John A. Olson, Jr.: It is hard to know exactly how to reconcile the two views on this, but it is what you have available. So, if you actually look at the number of tumors tested on those initial, that form the initial ideas, they are relatively small in all of these studies. And you can imagine, you know, what was the tumor tissue available? Well, it happened to be a very large adenoma that they got their hands on. Maybe those are the monoclonal ones, but actually one of the papers that I put on the table is actually an Arnold paper, and his group clearly shows that there are some polyclonal. He just chose to emphasize the monoclonal nature with the PRAD1. So, I think there is both going on.
With regard to the question of hyperplasia, I think what we are seeing in polyclonal is a prodrome of hyperplasia. And whether it is primary C cell hyperplasia that is classically described all the way back to Castleman or whether that actually represents a secondary drive to parathyroid hyperplasia, maybe by vitamin D deficiency, something else, and then much like secondary to tertiary, that chronic hyperplasia might pop by an unknown mechanism that is unknown to me, at least at this point.
